FLT3 and leukemia: The precise action of gilteritinib for AML cells with FLT3 genetic mutations in chromatin remodeling should be studied further when drug-sensitive and insensitive leukemia cells were compared with more comprehensive whole genome analyses such as RNA sequencing and chromatin immunoprecipitation (ChIP) sequencing.